All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
Introducing
Now you can personalise
your PsOPsA Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Topical treatment is often used as a first-line therapy for mild-to-moderate psoriasis and is available as cream, ointment, gel, foam, and lotion.1 Topical treatment works by reducing inflammation and reducing skin cell growth, but it can be less effective in patients with severe symptoms.1 Additionally, topical treatment can require increased effort and time to apply, which may result in low adherence.1
Here, we summarize a pilot validation study by Blome et al.1 published in British Journal of Dermatology assessing the feasibility of the Patient Benefit Index for Topical Treatment (PBI-TOP) tool in measuring the benefits of topical treatment in adult patients with psoriasis.1
Figure 1. Achievement of the highest importance therapy goals and preparation characteristics (results of the PBQ)*
PBQ, patient benefit questionnaire.
*Data from Blome, et al.1
Table 1. PBI-TOP scale internal consistency and correlation with convergent criteria*
PBI-TOP scale |
Internal consistency (Patients with PNQ data, n = 154) |
Correlation with convergent criteria (patients with PNQ and PBQ data, n = 121) |
||
---|---|---|---|---|
|
Cronbach’s α |
DLQI r (p value)† |
PASI r (p value)† |
BSA r (p value)† |
Overall effectiveness score |
0.94 |
–0.41 (<0.001) |
–0.32 (0.001) |
–0.22 (0.046) |
Effectiveness subscale |
||||
Symptoms |
0.90 |
–0.41 (<0.001) |
–0.27 (0.007) |
–0.16 (0.155) |
Quality of life |
0.94 |
–0.32 (0.002) |
–0.33 (0.002) |
–0.23 (0.055) |
Characteristics of the preparation score |
0.90 |
–0.34 (0.001) |
–0.19 (0.053) |
–0.19 (0.089) |
BSA, body surface area; DLQI, Dermatology Life Quality Index; PASI, Psoriasis Area and Severity Index; PNQ, patient needs questionnaire; PBI-TOP, Patient Benefit Index, version for topical treatment; PBQ, patient benefit questionnaire; r, correlation coefficient. |
Key learnings |
|
Blome C, Hülswitt L, Meineke A, et al. Goals and benefits in topical treatment for psoriasis: development and pilot validation of a patient-reported outcomes tool, the Patient Benefit Index for Topical Treatment (PBI-TOP). Br J Dermatol. 2024; 190(5):701-711. DOI: 10.1093/bjd/ljad484
Your opinion matters
Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox